The outbreak of SARS-CoV-2 is unlikely to be contained anytime soon with conventional medical technology. This beckons an urgent demand for novel and innovative interventions in clinical protocols, diagnostics, and therapeutics; to manage the current "disease X" and to be poised to counter its successor of like nature if one were to ever arise. To meet such a demand requires more attention to research on the viral-host interactions and on developing expeditious solutions, the kinds of which seem to spring from promising domains such as nanotechnology. Inducing activity at scales comparable to the viruses themselves, nanotechnology-based preventive measures, diagnostic tools and ther-apeutics for COVID-19 have been rapidly growing during the pandemic. This review covers the recent and promising nanomedicine-based solutions relating to COVID-19 and how some of these are possibly applicable to a wider range of viruses and pathogens. We also discuss the type, composition, and utility of nanostructures which play various roles specifically under prevention, diagnosis, and therapy. Further, we have highlighted the adoption and commercialization of some the solutions by large and small corporations alike, as well as providing herewith an exhaustive list on nanovaccines.

Prodrug‐mediated and nanomedicine‐mediated therapies stand at the forefront of cancer management today. However, a lot of recent research efforts have been focused on identifying novel strategies in treating tumor by combining the techniques and attributes of both prodrug‐mediated and nanomedicine‐mediated therapies into distinct prodrug‐based‐nanomedicine‐mediated (ProNaMed) therapies. Many of these amalgamated therapies exhibit augmented and sometimes synergistic antitumor effects which are engendered by the complementary and cooperative activities of the prodrugs and the nanostructures involved. Herein, the distinctive as well as overlapping features of prodrug‐mediated and nanomedicine‐mediated therapies with a few examples are expounded. Then, as some of the general trends observed in combined ProNaMed therapies are explored, the strategies used in such therapies along with some recent research examples and their respective therapeutic outcomes are discussed. Further, light is shed on the diverse manifestations of augmented antitumor effects and chemotherapeutic ameliorations which are noticeably materialized in many of the ProNaMed therapies. Fundamental insights are offered on why pursuing ProNaMed strategies may offer us better therapeutic solutions over isolated prodrug‐ or nanomedicine‐based strategies for tumor management.